Technical Data
B5001-61E
BTLA (B- and T-lymphocyte Associated Protein, B- and T-lymphocyte Attenuator, BTLA1, CD272, CD272 Antigen, FLJ16065, MGC129743) (FITC)
Description:
Human CD272 (BTLA, B and T Lymphocyte Attenuator) is a member of the Immunoglobulin superfamily and has sequence homology to PD-1 and CTLA4. It is expressed on T and B lymphocytes and other hemopoetic lineages. Engagement of this molecule by its ligand, CD270 (HVEM, a TNF superfamily member) can down regulate activated T and B cell responses. CD272 levels on antigen specific CD8+ T cells have been reported to decrease in viral specific, but not melanoma specific activated lines (1). Polymorphism of the CD272 molecule has been linked to rheumatoid arthritis (3).

Applications:
Suitable for use in FLISA and Flow Cytometry. Other applications not tested.

Recommended Dilution:
Flow Cytometry: 1:50
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and store at -20C. Aliquots are stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. FITC conjugates are sensitive to light.
TypeIsotypeCloneGrade
MabIgG111K2Affinity Purified
SizeStorageShippingSourceHost
120 tests-20CBlue IceHumanMouse
Concentration:
As reported
Immunogen:
Recombinant corresponding to soluble human CD272
Purity:
Purified by Protein A affinity chromatography.
Form
Supplied as a liquid in 50mM sodium phosphate, pH 7.5, 100mM potassium chloride, 150mM sodium chloride, 0.2% BSA, 0.04% sodium azide, 5% glycerol. Labeled with fluorescein isothiocyanate (FITC).
Specificity:
Recognizes human CD272 (BTLA). Binds to CD272 on the cell surface of human PBMC in Flow cytometry and to recombinant CD272-muIg in EIA. Blocks binding of Biotinylated CD270(HVEM)-muIg to CD272-muIg in EIA.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Derre L, DE Speiser, et al. (2010) J Clin Invest 120(1):157-167, 2. Otsuki N, Azuma M, et al. (2006) Biochem Biophys Res Com 344(4): 1121-1127, 3. Lin SC, Chan CH, et al. (2006) J Biomed Sci 13(6): 853-860, 4. Pasero C, D Olive, et al. (2009) Curr Mol Med 9(7): 911-927, 5. Gavrieli M, KM Murphy, et al. (2006) Adv Immunol 92: 152-185.